Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy

Summary

The primary objective: \*To measure the difference in the number of Ranibizumab therapies needed in 12 months in the Posterior Vitreous Detachment (PVD) positive and Posterior Vitreous Detachment (PVD) negative group. Secondary Objective: * To measure the mean change in visual acuity from Baseline to Month 12. * To measure the mean change in central retinal thickness per OCT from Baseline to Month 12

Timeline

Start

2007-10

Primary completion

2010-10

Completion

2010-10

Drugs

Indications